|Articles|April 15, 2003
- BioPharm International-04-01-2003
- Volume 16
- Issue 4
Guest Editorial: Benchmarking Biotech
Author(s)Michael E. Kamarck
by Michael Kamarck, Wyeth BioPharma
Advertisement
Articles in this issue
almost 23 years ago
Virus Inactivation in the 1990s and into the 21st Centuryalmost 23 years ago
Getting Ready for Risk-Based GMPsalmost 23 years ago
GMP Issues: Breaking Groundalmost 23 years ago
Optimized Nutrient Additives for Fed-Batch Culturesalmost 23 years ago
Inside Washington: GMP Progress ReportNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Fast Tracks Innovent’s Trispecific Antibody for Multiple Myeloma
2
FDA Priority Review of Subcutaneous Lecanemab Signals Shift in Alzheimer’s Treatment Delivery
3
Industrial-Scale Cell Therapy Automation Gains Traction with New Cellares Funding
4
HHS Releases New Guidance on Lowering Prescription Drug Prices Through DTC Programs
5
